TOP TEN perturbations for 1552598_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552598_at
Selected probe(set): 1552598_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552598_at (1552598_at) across 6673 perturbations tested by GENEVESTIGATOR:

BEZ235 study 1 (3.606 uM) / vehicle (DMSO) treated A2058 cell samples

Relative Expression (log2-ratio):-2.7762308
Number of Samples:4 / 4
Experimental BEZ235 study 1 (3.606 uM)
A2058 cells treated with 3.606 uM NVP-BEZ235 for 24hours. The concentration corresponding to the IC90 of BKM120. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:---
Control vehicle (DMSO) treated A2058 cell samples
A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine.

BEZ235 study 1 (IC90) / vehicle (DMSO) treated A2058 cell samples

Relative Expression (log2-ratio):-2.5217466
Number of Samples:4 / 4
Experimental BEZ235 study 1 (IC90)
A2058 cells treated with NVP-BEZ235 for 24hours at an IC90 concentration. Concentration of IC90 was judged by reduction of pAkt levels (S473P-Akt inhibition) and the value is not clear from the article. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:---
Control vehicle (DMSO) treated A2058 cell samples
A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine.

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)

Relative Expression (log2-ratio):2.1434317
Number of Samples:2 / 25
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; liver)
Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-2.1385117
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)

Relative Expression (log2-ratio):-2.0762606
Number of Samples:2 / 2
Experimental CNS cancer study 1 (PDX; glioma, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted).
Control CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted).

CNS cancer study 1 (PDX; glioblastoma, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)

Relative Expression (log2-ratio):-2.0721397
Number of Samples:3 / 2
Experimental CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted).
Control CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted).

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-2.0067663
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

GDC-0941 study 1 (3.606 uM) / GDC-0941 study 1 (IC50)

Relative Expression (log2-ratio):-1.9994936
Number of Samples:4 / 4
Experimental GDC-0941 study 1 (3.606 uM)
A2058 cells treated with 3.606 uM GDC-0941 for 24hours. The concentration corresponding to the IC90 of BKM120. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. GDC-0941 is a potent inhibitor of PI3Kα/δ, alternative names: [pictilisib] ATC code:---
Control GDC-0941 study 1 (IC50)
A2058 cells treated with GDC-0941 for 24hours at an IC50 concentration. Concentration of IC50 was judged by reduction of pAkt levels (S473P-Akt inhibition) as 114±3 nmol/l. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. GDC-0941 is a potent inhibitor of PI3Kα/δ, alternative names: [pictilisib] ATC code:---

GDC-0941 study 1 (IC90) / BEZ235 study 1 (IC90)

Relative Expression (log2-ratio):1.9458885
Number of Samples:4 / 4
Experimental GDC-0941 study 1 (IC90)
A2058 cells treated with GDC-0941 for 24hours at an IC90 concentration. Concentration of IC90 was judged by reduction of pAkt levels (S473P-Akt inhibition) and the value is not clear from the article. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. GDC-0941 is a potent inhibitor of PI3Kα/δ, alternative names: [pictilisib] ATC code:---
Control BEZ235 study 1 (IC90)
A2058 cells treated with NVP-BEZ235 for 24hours at an IC90 concentration. Concentration of IC90 was judged by reduction of pAkt levels (S473P-Akt inhibition) and the value is not clear from the article. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:---

glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-1.8900928
Number of Samples:2 / 3
Experimental glioma study 17 (small cell glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.